DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
PATHFINDER
Ipatasertib (IPA) combined with non-taxane chemotherapy (CT) for patients (pts) with previously treated advanced triple-negative breast cancer (aTNBC): The PATHFINDER phase IIa trial.
BREAST
ASCO
2024
ANALLISA
PHASE II Study To Assess The Efficacy Of Niraparib Rechallenge Treatment After Complete Secondary Cytoreduction In Ovarian Cancer Patients With Oligometastatic Progression: The ANALLISA Study
OVARIAN
IGCS
2024
I3LUNG
The impact of decision tools during oncological consultation with lung cancer patients: a systematic-review within the i3LUNG project
LUNG
(Journal) Cancer Medicine
2024
I3LUNG
I3LUNG: Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy
LUNG
ESMO
2024
TUXEDO-3
Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.
LUNG
ASCO
2024
DEBBRAH
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
BREAST
(Journal) ESMO Open
2024
ORPHEUS
Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study
PENILE
(Journal) European Urology Oncology
2024
I3LUNG
The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project
LUNG
(Journal) Nature Cancer
2024
OPHELIA
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: the OPHELIA phase 2 study
BREAST
(Journal) The Breast
2024
PHERGAIN
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
BREAST
(Journal) The Journal of Nuclear Medicine
2024
PHERGain
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and
pathological complete response (pCR) in HER2-positive early breast cancer (EBC):
An exploratory analysis of the PHERGain trial
BREAST
(Journal) Breast Cancer Research and Treatment
2024
ABIGAIL
ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria
BREAST
ESMO
2024
Other MEDSIR related articles
